Ata uhi

The cost associated with administering risperidone long-acting injections in the Australian community

<p>Abstract</p> <p>Background</p> <p>Risperidone long-acting injection (LAI) is mostly administered twice weekly to people with schizophrenia by nurses at community mental health centres (CMHC) or through mobile outreach visits. This study estimates the cost of resource...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Hertel Judy (Author), Schrover Rudolf (Author), Lambert Tim (Author), Dalton Andrew (Author), Smith Dell (Author)
Hōputu:	Pukapuka
I whakaputaina:	BMC, 2011-09-01T00:00:00Z.
Ngā marau:	article
Urunga tuihono:	Connect to this object online.
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Formulation development and pharmacokinetic studies of long acting in situ depot injection of risperidone
mā: Vineet Dubey, me ētahi atu.
I whakaputaina: (2022)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
mā: Trevor A. Stump, PharmD, BCPP, me ētahi atu.
I whakaputaina: (2021)

Training student pharmacists to administer long-acting injectable medications
mā: Megan J. Ehret, PharmD, MS, BCPP, me ētahi atu.
I whakaputaina: (2024)

Long-Acting Risperidone Dual Control System: Preparation, Characterization and Evaluation In Vitro and In Vivo
mā: Xieguo Yan, me ētahi atu.
I whakaputaina: (2021)

Risperidone Controlled Release Microspheres Based on Poly(Lactic Acid)-Poly(Propylene Adipate) Novel Polymer Blends Appropriate for Long Acting Injectable Formulations
mā: Stavroula Nanaki, me ētahi atu.
I whakaputaina: (2018)

Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations
mā: Yifei Liu, me ētahi atu.
I whakaputaina: (2023)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
mā: John M. Kane, me ētahi atu.
I whakaputaina: (2023)

Long-Acting Injectable Naltrexone for the Management of Patients with Opioid Dependence
mā: Kimberly L. Kjome, me ētahi atu.
I whakaputaina: (2011)

Long-Acting Injectable naltrexone for the Management of patients with Opioid Dependence
mā: Kimberly L. Kjome, me ētahi atu.
I whakaputaina: (2011)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
mā: Francisco José Toja-Camba, me ētahi atu.
I whakaputaina: (2021)

Searching for a long-acting injectable formulation for the antiretroviral dolutegravir
mā: Anderson Aparecido de Marchi, me ētahi atu.
I whakaputaina: (2019)

The Willingness of Community Psychiatric Management Physicians to Preferentially Recommend Long-Acting Injections in Beijing
mā: Lefan Jin, me ētahi atu.
I whakaputaina: (2021)

Promises and potential pitfalls of long-acting injectable pre-exposure prophylaxis
mā: Carey Pike, me ētahi atu.
I whakaputaina: (2023)

Long-Acting Injectable Antipsychotics-A Review on Formulation and In Vitro Dissolution
mā: Magdalena Markowicz-Piasecka, me ētahi atu.
I whakaputaina: (2023)

Pharmacist Administration of Long-Acting Injectable Antipsychotics to Community-Dwelling Patients: A Scoping Review
mā: Andrea L. Murphy, me ētahi atu.
I whakaputaina: (2023)

Risperidone-induced hyperpigmentation
mā: Pooja Bains, me ētahi atu.
I whakaputaina: (2019)

Risperidone Induced Eruptions
mā: Bhatia M . S
I whakaputaina: (2002)

Risperidone-induced angioedema
mā: Caitlin Burton, PharmD, BCPP, me ētahi atu.
I whakaputaina: (2024)

Correlates of weight gain during long-term risperidone treatment in children and adolescents
mā: Calarge Chadi, me ētahi atu.
I whakaputaina: (2012)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
mā: Hodgson RE
I whakaputaina: (2019)

Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosy.
mā: Aurélie Chauffour, me ētahi atu.
I whakaputaina: (2023)

Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics
mā: Shubhra Mace, me ētahi atu.
I whakaputaina: (2019)

Patients' satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
mā: Christina Darden, me ētahi atu.
I whakaputaina: (2021)

A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder
mā: Chue P, me ētahi atu.
I whakaputaina: (2016)

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
mā: David D. Kim, me ētahi atu.
I whakaputaina: (2021)

Assessment of oral overlap with antipsychotic long-acting injectables initiated in an inpatient setting
mā: Tran Jennifer T. PharmD, me ētahi atu.
I whakaputaina: (2023)

An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia
mā: Pandina Gahan, me ētahi atu.
I whakaputaina: (2012)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting [Corrigendum]
mā: Hodgson RE
I whakaputaina: (2019)

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients
mā: Siddhesh A Kamat, me ētahi atu.
I whakaputaina: (2015)

Risperidone for Aggressive Behavior in ADHD
mā: J Gordon Millichap
I whakaputaina: (2007)

Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report
mā: Blanca Fernández-Abascal, me ētahi atu.
I whakaputaina: (2021)

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
mā: Mahlich J, me ētahi atu.
I whakaputaina: (2015)

Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate
mā: Katy Mason, me ētahi atu.
I whakaputaina: (2021)

Preparation and in vitro/in vivo evaluation of PLGA microspheres containing norquetiapine for long-acting injection
mā: Park CW, me ētahi atu.
I whakaputaina: (2018)

Development of Mechanistic In Vitro-In Vivo Extrapolation to Support Bioequivalence Assessment of Long-Acting Injectables
mā: Daniela Amaral Silva, me ētahi atu.
I whakaputaina: (2024)

Should Intra-Articular Steroidal Injection be Administered in TMJ Disorders
mā: Kaustubh Sansare, me ētahi atu.
I whakaputaina: (2004)

The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study
mā: Walling DP, me ētahi atu.
I whakaputaina: (2021)

Flash Chromatography Application for Risperidone Purification
mā: G. S. Trush, me ētahi atu.
I whakaputaina: (2015)

Model-informed target product profiles of long-acting-injectables for use as seasonal malaria prevention
mā: Lydia Burgert, me ētahi atu.
I whakaputaina: (2022)

Model-informed target product profiles of long-acting-injectables for use as seasonal malaria prevention.
mā: Lydia Burgert, me ētahi atu.
I whakaputaina: (2022)